SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma moves up after entering into worldwide license agreement for SCD044

29 May 2020 Evaluate
Sun Pharmaceutical Industries is currently trading at Rs. 462.00, up by 2.75 points or 0.60% from its previous closing of Rs. 459.25 on the BSE.

The scrip opened at Rs. 459.50 and has touched a high and low of Rs. 468.85 and Rs. 458.75 respectively. So far 126726 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 504.85 on 27-Apr-2020 and a 52 week low of Rs. 315.20 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 475.65 and Rs. 443.10 respectively. The current market cap of the company is Rs. 111209.18 crore.

The promoters holding in the company stood at 54.69%, while Institutions and Non-Institutions held 32.37% and 12.94% respectively.

Sun Pharma Advanced Research Company (SPARC) and Sun Pharmaceutical Industries (Sun Pharma) and includes its subsidiaries and/or associate companies have entered into a worldwide license agreement on the development and commercialization of SCD044 which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other autoimmune disorders. SCD044 is entering phase 2 clinical trials.

Under terms of the license agreement, Sun Pharma will pay SPARC an upfront payment of $20 million. SPARC will also be eligible to receive up to $125 million as milestone payments contingent upon the achievement of clinical, regulatory and sales milestones, as well as tiered royalties on sales. Sun Pharma will be responsible for the development, regulatory filings, manufacturing and commercialization of the product globally.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma. Inds. Share Price

1869.20 3.25 (0.17%)
02-Jul-2026 09:15 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1869.20
Dr. Reddys Labs. 1330.00
Cipla 1462.30
Zydus Lifesciences 1110.45
Lupin 2397.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: